Regulatory planning for medical devices
Finnish medtech founders enter Thailand with a device, not a pathway.
The Thai medical device market is real and growing. A regional hub ambition backed by the Eastern Economic Corridor, a Medical Hub Board with active corridor development, and a government committed to positioning Thailand as Southeast Asia’s healthcare destination. For a Finnish medtech company with a validated device, strong clinical data, and home market commercial success, Thailand looks like the obvious next step.
What most founders discover in month three is that the step was longer than the map suggested.
Mistake one: starting with the device, not the entity
The Thai Food and Drug Administration will not accept a medical device registration from a foreign company. Before a single product submission is possible, a Thai legal entity must exist, registered with the Department of Business Development, with a shareholder structure compliant with the Foreign Business Act’s 49% foreign ownership cap.
That entity registration takes 3 to 6 months. Most Finnish founders discover this after the device is ready, the commercial timeline is set, and the first distributor conversation has already happened.
The correct sequence is entity first, device pathway second. The entity registration period is not dead time, it is the window for regulatory mapping, distributor relationship building, and hospital procurement research. Founders who treat it as an administrative delay lose six months of productive market preparation.
Mistake two: assuming EU regulatory equivalence
ISO 13485 certification is required. That much most Finnish founders know. What they underestimate is what comes after it.
For Class II medical devices without WHO prequalification, TFDA requires local clinical data in addition to international technical documentation. This does not always mean a full clinical trial, but it does mean a Thai institutional review board process, a local clinical partner, and a submission timeline of 9 to 18 months from entity establishment.
EU CE marking accelerates the technical file review but does not replace the Thai regulatory pathway. GMP audits are conducted on the manufacturing site, not just the documentation, and require scheduling with TFDA inspectors who operate on Thai government timelines. A Finnish founder who has navigated the EU MDR and assumes Thailand will be simpler is working from the wrong comparison.
Mistake three: underestimating the hospital procurement cycle
Most Finnish medtech devices target hospital or clinical settings in Thailand. Government hospital procurement, which represents the largest volume, operates through a centralised tender system with annual or biannual cycles. Missing a tender cycle means waiting up to 12 months for the next entry point.
Private hospital procurement moves faster but is relationship-dependent. The buying decision typically involves a clinical committee, a procurement officer, and a department head, three separate relationships requiring sustained cultivation, usually through a local clinical distributor who already has institutional access. Building these relationships from outside the country, without a local presence, is possible but slow.
What the pathway actually looks like
Month one to six: entity registration, legal structure established, TFDA pathway scoped, clinical partner identified, distributor conversations begun, no device submission yet.
Month six to twenty-four: TFDA registration running, distributor agreement signed with clear performance terms, first private hospital relationships under cultivation, government tender calendar mapped for next cycle.
Month twenty-four onwards: first legal sales, government tender submission if timeline aligns, clinical evidence building for ongoing commercial use.
The Finnish medtech founders who succeed in Thailand are not the ones with the best devices. They are the ones who understood that the pathway was the product, and built it before the device arrived.
